Cargando…

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

BACKGROUND: Several studies have reported the impact of single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) pathway genes on the efficacy of bevacizumab in metastatic colorectal cancer (mCRC), but results are still inconsistent. The PRODIGE 9 phase III study compared...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Rauglaudre, Bernadette, Sibertin-Blanc, Camille, Fabre, Aurélie, Le Malicot, Karine, Bennouna, Jaafar, Ghiringhelli, François, Taïeb, Julien, Boige, Valérie, Bouché, Olivier, Chatellier, Thierry, Faroux, Roger, François, Eric, Jacquot, Stéphane, Genet, Dominique, Mulot, Claire, Olschwang, Sylviane, Seitz, Jean-François, Aparicio, Thomas, Dahan, Laetitia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806434/ https://www.ncbi.nlm.nih.gov/pubmed/36601631 http://dx.doi.org/10.1177/17588359221141307

Ejemplares similares

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial
por: Aparicio, Thomas, et al.
Publicado: (2020)

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial
por: Bidard, François-Clément, et al.
Publicado: (2019)

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results
por: Aparicio, T, et al.
Publicado: (2018)

The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer
por: Le Corre, Delphine, et al.
Publicado: (2019)

Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59
por: Evrard, Camille, et al.
Publicado: (2022)

Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
por: Assenat, Eric, et al.
Publicado: (2019)

The prodigal son
por: Britten, Benjamin, 1913-1976
Publicado: (1990)

Cilia - the prodigal organelle
por: Beales, Phil, et al.
Publicado: (2012)

Les prodiges : piéce en deux parties /
por: Vauthier, Jean
Publicado: (1958)

Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case report
por: Sibertin-Blanc, Camille, et al.
Publicado: (2013)

The return of the prodigal Goldstone boson
por: Kapusta, Joseph I., et al.
Publicado: (1995)

Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 - ECKINOXE trial
por: Karoui, Mehdi, et al.
Publicado: (2015)

Prodigal: prokaryotic gene recognition and translation initiation site identification
por: Hyatt, Doug, et al.
Publicado: (2010)

The prodigal tongue: the love-hate relationship between British and American English
por: Murphy, Lynne
Publicado: (2018)

Growth rate evolution in improved environments under Prodigal Son dynamics
por: Collins, Sinéad
Publicado: (2016)

Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma
por: Canton, Clémence, et al.
Publicado: (2022)

Diagnostic Implication and Clinical Relevance of Ancillary Techniques in Clinical Pathology Practice
por: Makki, Jaafar S.
Publicado: (2016)

Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy – a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol
por: Boilève, Alice, et al.
Publicado: (2020)

Ancillary Care: From Theory to Practice in International Clinical Research
por: Pratt, Bridget, et al.
Publicado: (2013)

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
por: Kim, Stefano, et al.
Publicado: (2023)

Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas – PRODIGE 19 – FFCD1103 – ADCI002
por: Piessen, Guillaume, et al.
Publicado: (2013)

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
por: Kim, Stefano, et al.
Publicado: (2020)

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
por: Marisa, Laetitia, et al.
Publicado: (2021)

Ancillary mathematics
por: Massey, Harrie Stewart Wilson, et al.
Publicado: (1959)

STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact
por: Pons-Tostivint, Elvire, et al.
Publicado: (2021)

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Boige, Valérie, et al.
Publicado: (2023)

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma
por: Kim, Stefano, et al.
Publicado: (2022)

ProDiGe: Prioritization Of Disease Genes with multitask machine learning from positive and unlabeled examples
por: Mordelet, Fantine, et al.
Publicado: (2011)

Ancillary testing for diagnosis of brain death: a protocol for a systematic review and meta-analysis
por: Chassé, Michaël, et al.
Publicado: (2013)

Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy
por: Grard, Marion, et al.
Publicado: (2021)

Prognostic value of the PrP(C)-ILK-IDO1 axis in the mesenchymal colorectal cancer subtype
por: Ghazi, Alexandre, et al.
Publicado: (2021)

ICU Survivors Experience of ICU Diaries: An Ancillary Qualitative Analysis of the ICU Diary Study
por: Flahault, Cécile, et al.
Publicado: (2021)

Ancillary investigations in uveitis
por: Gupta, Vishali, et al.
Publicado: (2013)

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)
por: Vienot, Angélique, et al.
Publicado: (2023)

MAPK signaling regulates the efficacy of chemoimmunotherapy
por: Ghiringhelli, François
Publicado: (2022)

Signes et prodiges: il y a plus d’une façon d’écouter une histoire
por: Tudiver, Sari Lubitsch
Publicado: (2022)

Colorectal Cancer with Peritoneal Metastases: The Impact of the Results of PROPHYLOCHIP, COLOPEC, and PRODIGE 7 Trials on Peritoneal Disease Management
por: Sommariva, Antonio, et al.
Publicado: (2022)

Predictors of Chikungunya rheumatism: a prognostic survey ancillary to the TELECHIK cohort study
por: Gérardin, Patrick, et al.
Publicado: (2013)

SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis
por: Rousseau, Guillaume, et al.
Publicado: (2011)

Cerebral Oxygenation During Neonatal Intubation–Ancillary Study of the Prettineo–Study
por: Vedrenne-Cloquet, Meryl, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kgl80d5ojkceo3rtqj3mbdb0go